Capital International’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-30,511
| Closed | -$1.26M | – | 160 |
|
|
2022
Q3 | $1.26M | Buy |
30,511
+2,919
| +11% | +$121K | 0.09% | 147 |
|
|
2022
Q2 | $1.65M | Sell |
27,592
-1,520
| -5% | -$90.7K | 0.12% | 130 |
|
|
2022
Q1 | $2.11M | Sell |
29,112
-38,100
| -57% | -$2.77M | 0.12% | 133 |
|
|
2021
Q4 | $5.65M | Buy |
67,212
+1,978
| +3% | +$166K | 0.29% | 93 |
|
|
2021
Q3 | $5.88M | Sell |
65,234
-844
| -1% | -$76.1K | 0.32% | 84 |
|
|
2021
Q2 | $6.3M | Sell |
66,078
-340
| -0.5% | -$32.4K | 0.35% | 78 |
|
|
2021
Q1 | $7.56M | Sell |
66,418
-13,324
| -17% | -$1.52M | 0.46% | 67 |
|
|
2020
Q4 | $11M | Buy |
79,742
+1,016
| +1% | +$141K | 0.64% | 42 |
|
|
2020
Q3 | $6.47M | Buy |
78,726
+17,900
| +29% | +$1.47M | 0.44% | 62 |
|
|
2020
Q2 | $4.76M | Hold |
60,826
| – | – | 0.45% | 60 |
|
|
2020
Q1 | $2.7M | Hold |
60,826
| – | – | 0.3% | 83 |
|
|
2019
Q4 | $2.6M | Buy |
60,826
+17,905
| +42% | +$765K | 0.27% | 89 |
|
|
2019
Q3 | $1.84M | Buy |
42,921
+22,001
| +105% | +$941K | 0.28% | 90 |
|
|
2019
Q2 | $1.33M | Buy |
20,920
+1,494
| +8% | +$94.8K | 0.32% | 85 |
|
|
2019
Q1 | $1.35M | Buy |
19,426
+2,826
| +17% | +$196K | 0.32% | 84 |
|
|
2018
Q4 | $722K | Hold |
16,600
| – | – | 0.2% | 100 |
|
|
2018
Q3 | $1.27M | Sell |
16,600
-30,357
| -65% | -$2.32M | 0.4% | 75 |
|
|
2018
Q2 | $3.61M | Sell |
46,957
-13,700
| -23% | -$1.05M | 0.63% | 56 |
|
|
2018
Q1 | $3.09M | Sell |
60,657
-1,377
| -2% | -$70.2K | 0.55% | 62 |
|
|
2017
Q4 | $2.88M | Sell |
62,034
-204,466
| -77% | -$9.49M | 0.55% | 64 |
|
|
2017
Q3 | $14.2M | Buy |
266,500
+6,800
| +3% | +$362K | 0.94% | 45 |
|
|
2017
Q2 | $16.1M | Buy |
259,700
+52,982
| +26% | +$3.29M | 1.07% | 38 |
|
|
2017
Q1 | $14M | Buy |
206,718
+38,700
| +23% | +$2.62M | 0.91% | 40 |
|
|
2016
Q4 | $11.8M | Buy |
168,018
+11,018
| +7% | +$775K | 0.83% | 47 |
|
|
2016
Q3 | $11.1M | Buy |
+157,000
| New | +$11.1M | 0.79% | 49 |
|